Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE/HAIC + bevacizumab + sintilimab for unresectable advanced hepatocellular carcinoma
ChiCTR2300071146Phase 3Recruiting
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bevacizumab and sintilimab in hepatocellular carcinoma (HCC), sponsored by The Second Affiliated Hospital of Nanchang University. Primary endpoints: Progression-free survival and Objective response rate. Started May 2023; status: recruiting.
02
Drugs
bevacizumabsintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300071146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071146.